Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease

被引:16
作者
Feldkamp, J
Pascher, E
Schott, M
Goretzki, P
Seissler, J
Scherbaum, NA
机构
[1] Univ Dusseldorf, Dept Endocrinol, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Dept Surg, D-40225 Dusseldorf, Germany
[3] German Diabet Res Inst, D-40225 Dusseldorf, Germany
关键词
D O I
10.1210/jc.86.9.4250
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In Hashimoto's thyroiditis, Fas-induced apoptosis is one of the mechanisms leading to cell destruction, whereas thyroid tis. sue in Graves' disease is prevented from it. The soluble form of the Fas molecule produced by alternative splicing prevents from apoptosis. We measured soluble Fas in the sera of 112 patients with Graves' disease, 21 patients with toxic goiter, and 24 patients with subclinical hyperthyroidism due to suppressive therapy with levothyroxine after near-total resection of the thyroid gland for nodular goiter. Soluble Fas was increased in thyrotoxic patients, toxic goiter, and patients with subclinical hyperthyroidism. Decreased levels of soluble Fas were found in euthyroid patients with Graves' disease after surgery, whereas soluble Fas was normal in euthyroid patients with Graves' disease receiving antithyroid drug treatment and in patients in stable remission. There was a good correlation between soluble Fas with free T(s) (r=0.6) and free T(4) (r=0.5). Our results show that soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease.
引用
收藏
页码:4250 / 4253
页数:4
相关论文
共 42 条
[1]   Apoptosis and thyroiditis [J].
Arscott, PL ;
Baker, JR .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1998, 87 (03) :207-217
[2]   Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor [J].
Arscott, PL ;
Knapp, J ;
Rymaszewski, M ;
Bartron, JL ;
Bretz, JD ;
Thompson, NW ;
Baker, JR .
ENDOCRINOLOGY, 1997, 138 (11) :5019-5027
[3]  
Batteux F, 1999, J IMMUNOL, V162, P603
[4]   Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis [J].
Batteux, F ;
Lores, P ;
Bucchini, D ;
Chiocchia, G .
JOURNAL OF IMMUNOLOGY, 2000, 164 (04) :1681-1688
[5]   Fas and Fas ligand gene expression in autoimmune thyroiditis in BB/W rats [J].
Blüher, M ;
Krohn, K ;
Wallaschofski, H ;
Braverman, LE ;
Paschke, R .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 141 (05) :506-511
[6]   The role of Fas-mediated apoptosis in thyroid autoimmune disease [J].
Borgerson, KL ;
Bretz, JD ;
Baker, JR .
AUTOIMMUNITY, 1999, 30 (04) :251-264
[7]   Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells [J].
Bretz, JD ;
Arscott, PL ;
Myc, A ;
Baker, JR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (36) :25433-25438
[8]  
CASCINO I, 1995, J IMMUNOL, V154, P2706
[9]   PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE [J].
CHENG, JH ;
ZHOU, T ;
LIU, CD ;
SHAPIRO, JP ;
BRAUER, MJ ;
KIEFER, MC ;
BARR, PJ ;
MOUNTZ, JD .
SCIENCE, 1994, 263 (5154) :1759-1762
[10]   Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction [J].
Debatin, KM ;
Beltinger, C ;
Bohler, T ;
Fellenberg, J ;
Friesen, C ;
Fulda, S ;
Herr, I ;
Los, M ;
Scheuerpflug, C ;
Sieverts, H ;
Stahnke, K .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :405-410